Evidence map›Paper›PMID 36368887›Full record

ArticleTobacco control2024

IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.

Amal Khayat, Hagai Levine, Carla J Berg, Michal Shauly-Aharonov, Orly Manor, Lorien Abroms, Katelyn F Romm, Christina N Wysota, Yael Bar-Zeev

Abstract read
In one paragraph

Article in Tobacco control, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amal KhayatBraun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel amal.khayat@mail.huji.ac.il.ORCID 0000-0003-0525-4889
Hagai LevineBraun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-5597-4916
Carla J BergDepartment of Prevention and Community Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.ORCID 0000-0001-8931-1961
Michal Shauly-AharonovDepartment of Industrial Engineering, Jerusalem College of Technology, Jerusalem, Israel.
Orly ManorBraun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-0755-6314
Lorien AbromsDepartment of Prevention and Community Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.ORCID 0000-0001-6859-283X
Katelyn F RommDepartment of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0002-9552-0732
Christina N WysotaDepartment of Prevention and Community Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
Yael Bar-ZeevBraun School of Public Health and Community Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-1916-836X

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Assessing IQOS Marketing Influences and Consumer Behavior in Israel: Implications for the USR01CA239178 · NCI · GEORGE WASHINGTON UNIVERSITY · PI BERG, CARLA J, LEVINE, HAGAI · 2019 to 2021
$1.2M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA239178
6 · The paper itself

Abstract

backgroundTobacco regulation recently changed in Israel, including a partial advertisement ban. We assessed the impact of regulatory changes on Philip Morris International's (PMI) IQOS and cigarette advertisements.

methodsWeekly number of ads and weekly adspend of PMI's IQOS and cigarettes were analysed descriptively and using Quasi-Poisson regressions over time, across regulatory periods and in relation to subpopulations (general public, Arab, Russian and Ultra-Orthodox), from 25 December 2016 to 4 August 2020. Exponentiated coefficients (a value >1 indicates an increase) and 95% CIs are reported.

resultsThe average weekly number of ads and the average weekly adspend of IQOS were higher than cigarettes (42.22 vs 26.76 ads/week and 59 409 vs 45 613 new Israeli shekels/week; p<0.001 for both) during the study period, with exclusive IQOS advertisements during market penetration (December 2016 to May 2017). Variation in both outcomes was observed with regard to regulatory decisions. After the advertisement ban, there was a significant decrease in the weekly number of ads (IQOS: ß=0.04, 95% CI 0.002 to 0.20; cigarettes: ß=0.05, 95% CI 0.01 to 0.15) and weekly adspend (IQOS: ß=0.15, 95% CI 0.07 to 0.29; cigarettes: ß=0.31, 95% CI 0.17 to 0.53) for both products. The Ultra-Orthodox had significantly higher average weekly ads compared with the Arab population (IQOS: 0.67 vs 0.07; cigarettes: 2.74 vs 0.13; p

conclusionsIQOS and cigarette advertisements varied over time and appeared to have been impacted by regulatory changes. PMI invested more in IQOS advertisements than in cigarettes, with a partial advertisement ban decreasing both products' advertisements. PMI might be targeting the Ultra-Orthodox Jewish population which has a low smoking rate. Further research and surveillance are needed to better understand targeting strategies in order to inform tobacco control policy.

Indexed as

Electronic Nicotine Delivery SystemsTobacco ProductsAdvertisingHumansIsraelPopulation GroupsSmokingAdvertising and PromotionElectronic nicotine delivery devicesMedia

Identifiers

PMID36368887
PMCPMC10172385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.